Page last updated: 2024-11-05

1,2-dihydroxynaphthalene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,2-Dihydroxynaphthalene, also known as 1,2-naphthalenediol, is a polycyclic aromatic compound with two hydroxyl groups at the 1 and 2 positions of the naphthalene ring. It is a white solid that is soluble in organic solvents. 1,2-Dihydroxynaphthalene is an important intermediate in the synthesis of various pharmaceuticals, dyes, and other organic compounds. It is also a precursor to several naturally occurring compounds, including the plant pigment juglone. 1,2-Dihydroxynaphthalene has been investigated for its potential biological activities, including its antioxidant and anti-inflammatory properties. Research on 1,2-dihydroxynaphthalene focuses on its synthesis, its use as a building block for other compounds, and its potential applications in medicine and materials science.'

1,2-dihydroxynaphthalene: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11318
CHEMBL ID204543
CHEBI ID17435
SCHEMBL ID28483
MeSH IDM0144507

Synonyms (36)

Synonym
CHEBI:17435 ,
1,2-naphthohydroquinone
d1n ,
nsc401609
nsc-401609
C03012
574-00-5
naphthalene-1,2-diol
1,2-dihydroxynaphthalene
beta-naphthohydroquinone
1,2-naphthalenediol
1,2-dihydroxynaphthalene, technical grade
DB07610
CHEMBL204543 ,
D2299
unii-2r5017t335
nsc 401609
einecs 209-365-2
2r5017t335 ,
FT-0632416
SCHEMBL28483
dihydroxynaphthalene
DTXSID30205985
bdbm50049067
naphthalenediol, 1,2-
1-hydroxy-2-naphthol
1,2-naphthoquinol
mfcd00003959
AKOS027327446
Q27096830
CS-0095240
T71079
1,2-naphthalindiol
AS-57359
EN300-310625
PD005627
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
naphthalenediolA class of naphthalenediols that consists solely of naphthelene with any two of its hydrogens replaced by hydroxy groups. A 'closed class'.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
naphthalene degradation (aerobic)929
superpathway of aromatic compound degradation via 2-hydroxypentadienoate5095
naphthalene degradation to acetyl-CoA1138

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)IC50 (µMol)2.52001.10004.69009.5400AID1182274
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (31)

Processvia Protein(s)Taxonomy
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
lipid metabolic processTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
autophagyTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of autophagyTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of gene expressionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of gene expressionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
T cell differentiationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of type I interferon productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
response to lipopolysaccharideTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of interleukin-6 productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of interleukin-8 productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of tumor necrosis factor productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of natural killer cell proliferationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of toll-like receptor 3 signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of toll-like receptor 4 signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
phosphoanandamide dephosphorylationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of innate immune responseTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of B cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of T cell activationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cellular response to muramyl dipeptideTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of non-canonical NF-kappaB signal transductionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of protein K63-linked ubiquitinationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of p38MAPK cascadeTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
phosphatase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
SH3 domain bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
kinase bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
ubiquitin protein ligase bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
nucleusTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1182273Inhibition of LYP (unknown origin) incubated for 30 mins at 25 degC before addition of DiFMUP substrate in presence of 5 uM zinc acetate2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Inhibition of the lymphoid tyrosine phosphatase: the effect of zinc(II) ions and chelating ligand fragments on enzymatic activity.
AID261691Antiproliferative activity against human bladder carcinoma T24 cells2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Selective antiproliferative activity of hydroxynaphthyl-beta-D-xylosides.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID261690Antiproliferative activity against human fibroblast HFL1 cells2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Selective antiproliferative activity of hydroxynaphthyl-beta-D-xylosides.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1182275Inhibition of PTP1B (unknown origin)2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Inhibition of the lymphoid tyrosine phosphatase: the effect of zinc(II) ions and chelating ligand fragments on enzymatic activity.
AID1182276Inhibition of CD45 (unknown origin)2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Inhibition of the lymphoid tyrosine phosphatase: the effect of zinc(II) ions and chelating ligand fragments on enzymatic activity.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1182277Inhibition of YopH (unknown origin)2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Inhibition of the lymphoid tyrosine phosphatase: the effect of zinc(II) ions and chelating ligand fragments on enzymatic activity.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1182274Inhibition of LYP (unknown origin) using DiFMUP substrate incubated for 2 hrs2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Inhibition of the lymphoid tyrosine phosphatase: the effect of zinc(II) ions and chelating ligand fragments on enzymatic activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (7.69)18.7374
1990's4 (15.38)18.2507
2000's6 (23.08)29.6817
2010's11 (42.31)24.3611
2020's3 (11.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.36 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index5.01 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]